

Thomas Jefferson University Jefferson Digital Commons

Cardiology Faculty Papers

Department of Cardiology

1-1-2008

Sevoflurane enhances ethanol-induced cardiac preconditioning through modulation of protein kinase C, mitochondrial KATP channels, and nitric oxide synthase, in guinea pig hearts.

Kazuhiro Kaneda *Osaka Dental University*

Masami Miyamae Osaka Dental University

Shingo Sugioka Osaka Dental University

Chika Okusa Osaka Dental University

Yoshitaka Inamura Osaka Dental University

Let us know access to this document benefits you

Follow this and additional works at: http://jdc.jefferson.edu/cardiologyfp

Part of the <u>Cardiology Commons</u>

Recommended Citation

This article has been peer reviewed. It is the authors' final version prior to publication in Journal of the American College of Surgeons Volume 207, Issue 5, November 2008, Pages 758-762. The published version is available at . DOI: 10.1016/j.jamcollsurg.2008.06.341. Copyright © Elsevier Inc..

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Academic & Instructional Support & Resources Department (AISR). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Cardiology Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors

Kazuhiro Kaneda, Masami Miyamae, Shingo Sugioka, Chika Okusa, Yoshitaka Inamura, Naochika Domae, Junichiro Kotani, and Vincent M. Figueredo

As submitted to: *Anesthesia and Analgesia* and later published as: *Anesthesia and Analgesia* Volume 106, Issue 1, January 2008, Pages 9-16 10.1213/01.ane.0000297298.93627.36

Sevoflurane Enhances Ethanol-Induced Cardiac Preconditioning Through Modulation of Protein Kinase C, Mitochondrial K_{ATP} Channels, and Nitric Oxide Synthase, in Guinea Pig Hearts

Kazuhiro Kaneda, DDS*, Masami Miyamae, MD, PhD[£], Shingo Sugioka, DDS, PhD[#], Chika Okusa, DDS^{*}, Yoshitaka Inamura, DDS^{*}, Naochika Domae, MD, PhD[&], Junichiro Kotani, DDS, PhD[§], Vincent M. Figueredo, MD[¶]

*Postdoctoral Researcher, #Assistant Professor, §Professor, Department of Anesthesiology, Osaka Dental University, Osaka, Japan

[£]Assistant Professor, &Professor, Department of Internal Medicine, Osaka Dental University, Osaka, Japan

Institute for Heart and Vascular Health, Albert Einstein Medical Center, Philadelphia, USA

This study was supported in part by Grant-in-Aid for Scientific Research (C) 16592032 from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MM), the Osaka Dental University Joint Research Founds (MM, ND), and the Science Research Promotion Fund from the Promotion and Mutual Aid Corporation for Private Schools of Japan (ND).

Conflict of Interest: The authors have no conflicts of interest to report.

Key Words: sevoflurane, preconditioning, ethanol, mitochondrial K_{ATP} channel, protein kinase C, nitric oxide synthase

Corresponding Author & Reprints: Masami Miyamae, MD, PhD Department of Internal Medicine, Osaka Dental University 8-1 Kuzuha hanazono-cho Hirakata, Osaka 573-1121, Japan TEL : 81-72-864-3079, FAX : 81-72-864-3179 E-mail: kyotomiya@hotmail.com

Short Title: Sevoflurane and ethanol preconditioning

Implication Statement

Sevoflurane enhances cardiac preconditioning induced by regular ethanol consumption, an effect, mediated in part by PKC and mitochondrial K_{ATP} channels. Modulation of NOS expression by regular ethanol consumption may also play a role in this enhanced cardioprotection.

Abstract

Background: Volatile anesthetics and regular ethanol consumption induce cardioprotection mimicking ischemic preconditioning. We investigated whether sevoflurane enhances ethanol preconditioning and whether inhibition of protein kinase C (PKC) and mitochondrial K_{ATP} channels attenuated this enhanced cardioprotection. The effects of regular ethanol consumption on expression of inducible (iNOS) and endothelial (eNOS) nitric oxide synthase were determined. **Methods:** Isolated perfused guinea pig hearts underwent 30 min global ischemia and 120 min reperfusion (Control:CTL). The ethanol group (EtOH) received 2.5% ethanol in their drinking water for 6 weeks. Anesthetic preconditioning was elicited by 10 min exposure to sevoflurane (1 MAC; 2%) in ethanol (EtOH+SEVO) or non-ethanol (SEVO) hearts. PKC and mitochondrial K_{ATP} channels were inhibited with chelerythrine (CHE) and 5-hydroxydecanoate (5-HD) pretreatment, respectively. Contractile recovery was assessed by monitoring of left ventricular developed (LVDP) and end-diastolic (LVEDP) pressures. Infarct size was determined by triphenyltetrazolium chloride staining. Expression of iNOS and eNOS were determined by Western blot analysis.

Results: After ischemia-reperfusion, hearts from the EtOH, sevoflurane (SEVO), and EtOH+SEVO groups had higher LVDP and lower LVEDP compared with CTL. Infarct size was reduced in EtOH and SEVO hearts compared with CTL (27% and 23% vs. 45%, respectively, p<0.001). Sevoflurane further reduced infarct size in EtOH hearts (27% vs. 15%, p<0.001). CHE and 5-HD abolished cardioprotection in both SEVO and EtOH cardioprotected hearts. iNOS expression was reduced and eNOS expression was increased in EtOH hearts.

Conclusions: Sevoflurane enhances cardiac preconditioning induced by regular EtOH consumption. This effect is mediated in part by modulation of PKC and mitochondrial K_{ATP} channels, and possibly by altered modulation of NOS expression.

The number of words is 261.

Introduction

Volatile anesthetics induce cardiac preconditioning in a manner similar to ischemic preconditioning.¹ Since Kersten et al.², first documented anesthetic preconditioning with isoflurane, investigators have sought to elucidate the involved mechanisms mediating this cardioprotection. Recently, sevoflurane was shown to confer additional cardioprotection to late ischemic preconditioning, mediated via mitochondrial K_{ATP} channels.³ These data suggests that sevoflurane may enhance cardioprotection in myocardium, which is already preconditioned.

Epidemiological studies have shown that mortality rates for people who regularly drink alcohol in moderation are lower than in abstainers, primarily due to decreased fatal ischemic heart disease.⁴⁻⁷ Further, moderate alcohol consumers have lower mortality from myocardial infarction compared with abstainers.⁸ These beneficial cardiac effects may be due to the pleiotropic effects of ethanol on lipids⁹, platelets, and fibrinolytic activity.^{10,11} We have demonstrated that regular ethanol consumption renders hearts more tolerant to ischemia-reperfusion injury, to a degree similar to acute ischemic preconditioning.¹²⁻¹⁴ We found this ethanol-induced preconditioning is mediated through myocyte adenosine A₁ receptor^{12,13} and protein kinase C (PKC) activation.¹⁴ Ethanol and volatile anesthetics-induced cardiac preconditioning, thus, appear to share common signaling pathways. Guiraud et al.¹⁵, confirmed that the combination of ethanol and ischemic preconditioning were synergistic in reducing infarct size.

We hypothesized that anesthetic preconditioning with sevoflurane would enhance ethanol-induced myocardial preconditioning, and that this effect is potentially mediated by PKC activation and modulation of mitochondrial K_{ATP} channels.¹⁶ Both sevoflurane and *acute* ethanol exposure increase nitric oxide release.^{17,18} Thus, we examined the effect of *chronic* ethanol exposure on the expression of inducible and endothelial nitric oxide synthases (iNOS and eNOS).

Methods

This study was conducted in accordance with the Guidelines for Animals Research at Osaka Dental University (ODU), and with the approval of the Animal Experiment Committee of ODU, Osaka, Japan. Male Hartley guinea pigs were fed Lab Diet (RC4TM, Oriental Yeast, Tokyo, Japan) and given water *ad libitum*.

Isolated Heart Perfusion and Measurement of Function

Animals weighing 650-700g were given heparin (1000 units i.p.), then anesthetized with pentobarbital (60 mg/kg i.p). The hearts were excised and immediately arrested in cold isosmotic saline containing 20 mmol/L KCl. The aorta was cannulated and the isolated hearts perfused at 70 mmHg on a nonrecirculating isovolumic perfused heart apparatus, using a Krebs-Henseleit (KH) perfusate (mmol/L): 118 NaCl, 4.0 KCl, 2.52 CaCl₂, 24.8 NaHCO3, 1.7 MgSO4, 1.2 KH2PO4, 11.0 glucose, 0.5 EDTA and 8 units/L insulin. The perfusate was insufflated continuously with 95%O₂/5%CO₂. The hearts were paced at 240 beats/min using platinum-tipped electrodes connected to a Grass Instruments (Quincy, MA, USA) SD-5 stimulus generator. Left ventricular developed pressure (LVDP) was measured from a 2.5 French, high-fidelity micromanometer (Nihon-Kohden, Tokyo, Japan) passed into a compliant latex balloon inserted into the LV, and recorded on a PowerLab 2/20 Data Recording System (ADInstruments, Hayward, Australia). The balloon was connected to a Y-adapter with one end used to advance the micromanometer and the other used to fill the LV balloon with bubble-free water to an end-diastolic pressure (LVEDP) of 10 mmHg. The maximum rate of increase of LV pressure (+dP/dtmax) and the minimum rate of decrease of LV pressure (-dP/dt_{min}) were calculated using ChartTM5 (ADInstruments). Coronary flow

(CF) was measured by collecting effluent. Global ischemia was achieved by clamping the aortic inflow line. Temperature of the heart was continuously monitored by a digital thermometer (PTW-100A, Unique Medical, Japan). During ischemia, hearts were maintained at 37 °C by enclosure in a water-jacketed air chamber. Warmed perfusate kept in the lower part of the chamber saturated the air with humidity and prevented cooling by evaporation.

Experimental Protocol

Animals were assigned to one of 8 groups (n=10 each; Figure 1). Animals were initially given 1.25 % ethanol in their drinking water for 1 week and then 2.5 % ethanol for 6 weeks. Serum ethanol levels at time of sacrifice were measured by gas chromatography (Shimadzu, Kyoto, Japan). Liver enzymes were measured to rule out the possible liver tissue damage.

After a 20 min equilibration, baseline LVDP, LVEDP and CF were recorded. All hearts were subjected to 30 min of ischemia followed by 120 min of reperfusion. Anesthetic preconditioning was elicited by administration of sevoflurane (2%) for 10 min followed by 10 min washout before ischemia. Sevoflurane was insufflated by passing the $95\%O_2/5\%CO_2$ gas mixture through a calibrated vaporizer (ACOMA, Tokyo, Japan). Samples of coronary perfusate were collected anaerobically from the aortic cannula for measurement of sevoflurane concentration by an organic vapor sensor (OSP, Saitama, Japan). To investigate the role of PKC and mitochondrial K_{ATP} channels activation, their inhibitors chelerythrine (CHE) and 5-hydroxydecanoate (5-HD) were administered for 20 min, starting 10 min before sevoflurane (EtOH+SEVO+CHE, EtOH+SEVO+5HD) or saline

vehicle (CTL+CHE, CTL+5HD) administration. Chelerythrine (Alexis-Calbiochemicals, Tokyo, Japan) and 5-HD (Sigma Chemicals, St. Louis, MO, USA) were dissolved in distilled water, and added to the KH perfusate to a final concentration of 10 μ M and 200 μ M, respectively. We performed experiments in the following order: first a CTL, followed by ETOH, SEVO, ETOH+SEVO, CTL+CHE, and so forth until the first series of experiments were completed. This sequence was repeated a total of ten times.

Determination of Myocardial Infarct Size

At the end of experiments, the hearts were quickly frozen at -80 °C for 15 min, then sliced into 2 mm thick transverse sections from apex to base (6 slices/heart). After removing the right ventricle and defrosting, each slice was weighed and incubated at 37 °C with 1% triphenyltetrazolium chloride (Sigma Chemicals) in phosphate buffer (pH 7.4) for 10 min and then fixed in 10% formalin for at least 5 h to distinguish red stained viable tissue from pale unstained necrotic tissue.¹⁹ Each slice was photographed and the necrotic area was determined using Adobe Photoshop[®] CS (Adobe, CA, USA) and multiplied by the weight of the slice, then expressed as a fraction of left ventricle.

Western Blot Analysis

Separate experiments were performed (n=4 in each group) to examine iNOS and eNOS expression. Myocardial tissue samples were collected before ischemia, and homogenized in ice-cold homogenizing buffer containing in mM: 250 sucrose, 20 HEPES (pH 7.5), 10 KCl, 2 EGTA, 2 MgCl₂, 25 NaF, 50 β -glycerophosphate, 1 Na₃VO₄, 1 PMSF, 1% Triton X and protease inhibitor leupeptin (10 μ g/ml). The homogenate was centrifuged at 1000g and 4 °C

for 5 min. The supernatant was re-centrifuged at 10000g and 4 °C for 15 min. The protein concentration was estimated with a Bradford assay. Equivalent amounts (50 µg) of protein samples were loaded and separated on a 5-10% SDS-PAGE gradient gel, then electrically transferred overnight to a PVDF membrane (Millipore Co., Billerica, USA). After blocking with 5% skim milk in Tris-buffered saline containing 0.1% Tween-20 (TBS-T), the membranes were incubated for 2 hr at 4 °C in TBS-T containing 5% milk and 1:200 dilution of rabbit primary antibody for iNOS and eNOS (H-174 and H-159, Santa Cruz Biotechnology, USA). Membranes were incubated with a 1:1000 dilution of horseradish peroxidase–labeled anti-rabbit immunoglobulin G (NA 934V, GE Healthcare, UK). The same blot was stripped and re-blotted with antibodies to α -tubulin to confirm equal protein loading. Bound antibody signals were detected with enhanced chemiluminescence (Pierce Biotechnology, IL, USA) and visualized using VersaDoc 5000[®] Imaging System (Bio-Rad). Quantitative analysis of the band densities was performed by Quantity One[®] software (Bio-Rad).

Statistical Analysis

All data are expressed as mean \pm SD. Two-factor repeated-measures analysis of variance was used to evaluate differences over time between groups. If differences were observed, a Tukey post-hoc test was used to confirm the significance of differences between groups. The differences in expressions of iNOS and eNOS were determined by unpaired Student's *t* test. Power analysis demonstrated a sample size of n=10 hearts per group was sufficient. A value of p<0.05 was considered statistically significant.

Results

Of a total of 92, 10 hearts were not used secondary to intractable ventricular fibrillation after reperfusion (four in CTL, three in CTL+CHE, two in CTL+5HD and one EtOH+SEVO+CHE) and 2 hearts were not used due to aortic rupture. Additional hearts were studied until each group had n=10 successful experiments. There was no significant difference in body weight among groups. Serum ethanol levels at time of sacrifice was 2.7±0.5 mmol/L. Ethanol was not detected in the effluent of the 10 EtOH hearts sampled after 50 min washout but before ischemia or sevoflurane exposure. There was no difference in liver enzymes levels between EtOH and CTL animals. The concentration of sevoflurane in the coronary perfusate after 10 min of exposure was 0.36±0.09 mM. Sevoflurane was not detected in the effluent during the baseline, ischemic, and reperfusion periods.

Hemodynamics

Baseline LVDP, +dP/dt_{max}, -dP/dt_{min} and CF were similar among the 8 groups. Administration of sevoflurane or treatment with CHE and 5-HD did not significantly affect LVDP or CF. Recovery of LVDP was greater in EtOH, SEVO, and EtOH+SEVO compared with CTL throughout the reperfusion period. Recovery of LVDP in EtOH+SEVO hearts was abolished by administration of CHE and 5-HD. Treatment with CHE and 5-HD alone did not affect the recovery of LVDP. LVEDP increased to 600% of baseline in CTL after ischemiareperfusion. The increase in LVEDP was significantly less in EtOH, SEVO, and EtOH+SEVO compared with CTL hearts during reperfusion period. LVEDP in CHE and 5-HD groups was similar to that of CTL hearts. Treatment with CHE and 5-HD alone did not affect the increased LVEDP. All groups had reduced $+dP/dt_{max}$ after reperfusion compared with baseline. Recovery of $+dP/dt_{max}$ was significantly greater in SEVO, EtOH and SEVO+EtOH compared with CTL hearts, but not in hearts pretreated with CHE and 5-HD. Changes of $-dP/dt_{min}$ during the reperfusion period were similar to those of $+dP/dt_{max}$. There was no significant difference in CF among all groups throughout the experiment. This suggests that changes in CF could not account for the improved contractile recovery of SEVO or ETOH hearts (Table 1).

Myocardial Infarct Size

Myocardial infarct size in EtOH and SEVO groups was significantly reduced by approximately 50% compared with control hearts (EtOH:27±6%, SEVO:23±7% vs. CTL:45±11%, p<0.001). The administration of sevoflurane in EtOH hearts decreased infarct size compared with EtOH alone (EtOH+SEVO:15±4%, vs. EtOH: 27±6%, p<0.001). Myocardial infarct size in EtOH and SEVO hearts pretreatment with CHE and 5-HD was not different compared with CTL hearts (EtOH+SEVO+CHE:44±12%, p=0.777, EtOH+SEVO+5-HD:45±9%, p=0.852 vs. CTL). Treatment with CHE and 5-HD alone did not affect the infarct size compared with the CTL group (p=0.884; 0.355, respectively, vs. CTL) (Figure 2).

Western Blot analysis

The densities of iNOS and eNOS were normalized against that of CTL. Chronic EtOH consumption increased expression of eNOS whereas it reduced expression of iNOS compared with the CTL groups (Figure 3). Ethanol-treated and CTL hearts showed similar

iNOS and eNOS expression in the presence of CHE and 5-HD with and without sevoflurane exposure (data not shown).

Discussion

We found that pretreatment with sevoflurane and regular ethanol consumption equally preconditioned hearts against ischemia-reperfusion injury. Furthermore, sevoflurane enhanced the cardioprotective effect of regular ethanol consumption resulting in smaller infarct size. This protection was abolished by inhibiting PKC or mitochondrial K_{ATP} channels, suggesting their role in mediating the observed cardiac preconditioning. Finally, we found that regular ethanol consumption increased eNOS expression and reduced iNOS expression. Our finding that hearts treated with sevoflurane or ethanol showed similar improved functional recovery, demonstrated by increased LVDP and lower LVEDP, as well as a nearly 50% decrease in infarct size, following ischemia-reperfusion is consistent with previous reports.^{12,20,21} We observed that despite a significant reduction of myocardial infarct size induced by the combination of ethanol and sevoflurane, compared with either preconditioning therapy alone, recovery of LVDP during reperfusion was comparable among SEVO, EtOH and SEVO+EtOH hearts. This disparity between the functional recovery and infarct size might be explained by myocardial stunning from global ischemia that affected a greater area of the LV than that susceptible to infarction.^{22,23}

A new finding of this study was that ethanol-induced preconditioning is enhanced by anesthetic-induced preconditioning. A possible mechanism for this effect may be that ethanol does not completely activate the signal transduction pathways eliciting cardioprotection. We previously demonstrated that exposure to 2.5 % ethanol for 6 weeks reduces ischemia-reperfusion injury to the same degree as 5%, 10%, and 20% ethanol for 6 to 12 weeks.¹² Thus, the ethanol dose used in the present study should induce the maximum ethanol-induced cardiac protection. Similarly, the sevoflurane dose (2%) used in the present

study has been previously shown to produce the maximum cardiac protection.²⁴ The additive preconditioning effect by the combination of sevoflurane and ethanol suggests that there are some differences in either their mechanisms of action or degree of signaling activation.

Opening of K_{ATP} channels is an important step in the signal transduction cascade of cardiac protection from both volatile anesthetics²¹ and chronic ethanol exposure.²⁵ For example, Zaugg et al.²⁶, demonstrated that sevoflurane increased mitochondrial flavoprotein oxidation, an index of mitochondrial K_{ATP} channel activity, and that this effect was completely abolished by chelerythrine (2 μ M) in rat cardiomyocytes. Mitochondrial K_{ATP} channels are activated by NO²⁷, a key mediator in late ischemic preconditioning.²⁸ Others have shown that preconditioning with sevoflurane enhances the increased NO effluent induced by bradykinin and nitroprusside in isolated guinea pig hearts.¹⁷ Moreover, ethanol consumption increases serum NO production 30 min after drinking in humans.²⁹ Our data and prior reports suggest that increased eNOS expression due to chronic ethanol consumption could result in increased NO production. This is consistent with a previous study demonstrating that ethanol increases NO production through modulation of eNOS expression.¹⁸ Recently, the importance of eNOS in myocardial ischemic protection was demonstrated in an eNOS knockout mice model.³⁰ Thus, augmentation of mitochondrial K_{ATP} channel activity by increased NO with the combination of sevoflurane and chronic ethanol consumption might explain the additive cardioprotection in SEVO+EtOH hearts.

Previous experiments suggest that inflammation plays a role ischemia-reperfusion injury.³¹ NO derived from iNOS mediates cardiac dysfunction by inducing production of pro-inflammatory cytokines.³² Cytokines such as interleukin-1 β , interleukin-6, and tumor necrosis factor-alpha (TNF- α) are up-regulated rapidly in response to myocardial ischemia.³³

Sevoflurane has been shown to reduce the production of TNF- α in patients undergoing coronary bypass surgery.³⁴ Interestingly, a recent study found that the late phase of ethanol's myocardial preconditioning correlated with reduced leukocyte-endothelial cell adhesive interactions, suggesting an anti-inflammatory effect.³⁵ In the present study, with a crystalloid-perfused heart, leukocyte-endothelial cell adhesive interactions, though, is not a factor. Nevertheless, EtOH hearts demonstrated reduced iNOS expression before ischemia compared with CTL. Thus, regular ethanol consumption could attenuate the inflammatory response to myocardial ischemia resulting from increased NO production via iNOS. Although iNOS is thought to be absent in myocytes under physiologic conditions, there is evidence that iNOS is present in small vessel endothelium, vascular smooth muscle cells, and immune cells that infiltrate the heart.³⁶

Recent studies demonstrate that acute (as opposed to chronic) ethanol exposure fails to exert a cardioprotection when ethanol is present during ischemia-reperfusion.³⁷ Although not withdrawn from the drinking water before sacrifice in this study, serum ethanol levels were low (2.7 ± 0.5 mmol/L) at the time of sacrifice. Ethanol was washed out prior to ischemia using a crystalloid ethanol-free buffer. Ethanol was not detected after 50 min perfusion in the effluent. Ethanol freely diffuses in myocytes. Thus, tissue levels of ethanol were likely negligible at the time of study.

A limitation of the present study is that we did not directly measure PKC levels and mitochondrial K_{ATP} channel activity before and during ischemia-reperfusion. The doses of CHE and 5-HD used in the present study have been previously found to reduce PKC levels and inhibit mitochondrial K_{ATP} channel activity, respectively.^{14,38} Furthermore, we and other investigators have previously shown that the same concentrations of CHE and 5-HD inhibit

the preconditioning-like effects of ethanol or sevoflurane alone.^{14,25,38} Prolonged ingestion of ethanol may lead to changes in heart rate and blood pressure. Although we did not measure heart rate or blood pressure prior to sacrifice in this study, a previous study demonstrated that feeding 10 % ethanol (a much higher dose) for 40 weeks to guinea pigs did not alter hemodynamics compared with control³⁹. Finally, animals were not randomized to each study group although the order of study was standardized.

In conclusion, sevoflurane enhances cardiac preconditioning induced by regular ethanol consumption. Our findings suggest that PKC and mitochondrial K_{ATP} channels play a role in mediating this cardioprotection. NOS expression is altered by regular ethanol consumption.

References

- Zaugg M, Lucchinetti E, Uecker M, Pasch T, Schaub MC. Anaesthetics and cardiac preconditioning. Part I. Signalling and cytoprotective mechanisms. Br J Anaesth 2003;91:551-65.
- 2. Kersten JR, Schmeling TJ, Pagel PS, Gross GJ, Warltier DC. Isoflurane mimics ischemic preconditioning via activation of K_{ATP} channels: reduction of myocardial infarct size with an acute memory phase. Anesthesiology 1997;87:361-70.
- Müllenheim J, Ebel D, Bauer M, Otto F, Heinen A, Frassdorf J, Preckel B, Schlack W. Sevoflurane confers additional cardioprotection after ischemic late preconditioning in rabbits. Anesthesiology 2003;99:624-31.
- 4. Klatsky AL, Armstrong MA, Friedman GD. Risk of cardiovascular mortality in alcohol drinkers, ex-drinkers and nondrinkers. Am J Cardiol 1990;66:1237-42.
- Fuchs CS, Stampfer MJ, Colditz GA, Giovannucci EL, Manson JE, Kawachi I, Hunter DJ, Hankinson SE, Hennekens CH, Rosner B. Alcohol consumption and mortality among women. N Engl J Med 1995;332:1245-50.
- Rimm EB, Giovannucci EL, Willett WC, Colditz GA, Ascherio A, Rosner B, Stampfer MJ. Prospective study of alcohol consumption and risk of coronary disease in men. Lancet 1991;338:464-8.
- Thun MJ, Peto R, Lopez AD, Monaco JH, Henley SJ, Heath CW, Jr., Doll R. Alcohol consumption and mortality among middle-aged and elderly U.S. adults. N Engl J Med 1997;337:1705-14.
- 8. Mukamal KJ, Maclure M, Muller JE, Sherwood JB, Mittleman MA. Prior alcohol consumption and mortality following acute myocardial infarction. Jama 2001;285:1965-70.
- Gaziano JM, Buring JE, Breslow JL, Goldhaber SZ, Rosner B, VanDenburgh M, Willett W, Hennekens CH. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N Engl J Med 1993;329:1829-34.
- Pikaar NA, Wedel M, van der Beek EJ, van Dokkum W, Kempen HJ, Kluft C, Ockhuizen T, Hermus RJ. Effects of moderate alcohol consumption on platelet aggregation, fibrinolysis, and blood lipids. Metabolism 1987;36:538-43.

- 11. Ridker PM, Vaughan DE, Stampfer MJ, Glynn RJ, Hennekens CH. Association of moderate alcohol consumption and plasma concentration of endogenous tissue-type plasminogen activator. Jama 1994;272:929-33.
- 12. Miyamae M, Diamond I, Weiner MW, Camacho SA, Figueredo VM. Regular alcohol consumption mimics cardiac preconditioning by protecting against ischemia-reperfusion injury. Proc Natl Acad Sci U S A 1997;94:3235-9.
- 13. Miyamae M, Camacho SA, Zhou HZ, Diamond I, Figueredo VM. Alcohol consumption reduces ischemia-reperfusion injury by species-specific signaling in guinea pigs and rats. Am J Physiol 1998;275:H50-6.
- Miyamae M, Rodriguez MM, Camacho SA, Diamond I, Mochly-Rosen D, Figueredo VM. Activation of epsilon protein kinase C correlates with a cardioprotective effect of regular ethanol consumption. Proc Natl Acad Sci U S A 1998;95:8262-7.
- Guiraud A, de Lorgeril M, Boucher F, Berthonneche C, Rakotovao A, de Leiris J. Cardioprotective effect of chronic low dose ethanol drinking: insights into the concept of ethanol preconditioning. J Mol Cell Cardiol 2004;36:561-6.
- Hanley PJ, Daut J. K_{ATP} channels and preconditioning: a re-examination of the role of mitochondrial K_{ATP} channels and an overview of alternative mechanisms. J Mol Cell Cardiol 2005;39:17-50.
- 17. Novalija E, Fujita S, Kampine JP, Stowe DF. Sevoflurane mimics ischemic preconditioning effects on coronary flow and nitric oxide release in isolated hearts. Anesthesiology 1999;91:701-12.
- Venkov CD, Myers PR, Tanner MA, Su M, DE V. Ethanol increases endothelial nitric oxide production through modulation of nitric oxide synthase expression. Thromb Haemost 1999;81:638-42.
- Fishbein MC, Meerbaum S, Rit J, Lando U, Kanmatsuse K, Mercier JC, Corday E, Ganz W. Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. Am Heart J 1981;101:593-600.
- 20. Julier K, da Silva R, Garcia C, Bestmann L, Frascarolo P, Zollinger A, Chassot PG, Schmid ER, Turina MI, von Segesser LK, Pasch T, Spahn DR, Zaugg M. Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: a double-blinded, placebocontrolled, multicenter study. Anesthesiology 2003;98:1315-27.

- 21. Toller WG, Kersten JR, Pagel PS, Hettrick DA, Warltier DC. Sevoflurane reduces myocardial infarct size and decreases the time threshold for ischemic preconditioning in dogs. Anesthesiology 1999;91:1437-46.
- 22. Kloner RA, Jennings RB. Consequences of brief ischemia: stunning, preconditioning, and their clinical implications: part 2. Circulation 2001;104:3158-67.
- Cohen MV, Yang XM, Downey JM. Smaller infarct after preconditioning does not predict extent of early functional improvement of reperfused heart. Am J Physiol 1999;277:H1754-H61.
- 24. Yvon A, Hanouz JL, Haelewyn B, Terrien X, Massetti M, Babatasi G, Khayat A, Ducouret P, Bricard H, Gerard JL. Mechanisms of sevoflurane-induced myocardial preconditioning in isolated human right atria in vitro. Anesthesiology 2003;99:27-33.
- 25. Zhu P, Zhou HZ, Gray MO. Chronic ethanol-induced myocardial protection requires activation of mitochondrial K_{ATP} channels. J Mol Cell Cardiol 2000;32:2091-5.
- 26. Zaugg M, Lucchinetti E, Spahn DR, Pasch T, Schaub MC. Volatile anesthetics mimic cardiac preconditioning by priming the activation of mitochondrial K(ATP) channels via multiple signaling pathways. Anesthesiology 2002;97:4-14.
- 27. Sasaki N, Sato T, Ohler A, O'Rourke B, Marban E. Activation of mitochondrial ATP-dependent potassium channels by nitric oxide. Circulation 2000;101:439-45.
- Bolli R. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol 2001;33:1897-918.
- Matsuo S, Nakamura Y, Takahashi M, Ouchi Y, Hosoda K, Nozawa M, Kinoshita M. Effect of red wine and ethanol on production of nitric oxide in healthy subjects. Am J Cardiol 2001;87:1029-31: A6.
- 30. Sumeray MS, Rees DD, Yellon DM. Infarct size and nitric oxide synthase in murine myocardium. J Mol Cell Cardiol 2000;32:35-42.
- Torre-Amione G, Kapadia S, Lee J, Bies RD, Lebovitz R, Mann DL. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 1995;92:1487-93.
- 32. Csont T, Viappiani S, Sawicka J, Slee S, Altarejos JY, Batinic-Haberle I, Schulz R. The involvement of superoxide and iNOS-derived NO in cardiac dysfunction induced by pro-inflammatory cytokines. J Mol Cell Cardiol 2005;39:833-40.
- 33. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res 2004;94:1543-53.

- 34. Nader ND, Li CM, Khadra WZ, Reedy R, Panos AL. Anesthetic myocardial protection with sevoflurane. J Cardiothorac Vasc Anesth 2004;18:269-74.
- 35. Yamaguchi T, Dayton C, Shigematsu T, Carter P, Yoshikawa T, Gute DC, Korthuis RJ. Preconditioning with ethanol prevents postischemic leukocyte-endothelial cell adhesive interactions. Am J Physiol Heart Circ Physiol 2002;283:H1019-30.
- Hare JM, Colucci WS. Role of nitric oxide in the regulation of myocardial function. Prog Cardiovasc Dis 1995;38:155-66.
- 37. Krenz M, Baines CP, Yang XM, Heusch G, Cohen MV, Downey JM. Acute ethanol exposure fails to elicit preconditioning-like protection in situ rabbit hearts because of its continued presence during ischemia. J Am Coll Cardiol 2001;37:601-7.
- 38. Riess ML, Novalija E, Camara AK, Eells JT, Chen Q, Stowe DF. Preconditioning with sevoflurane reduces changes in nicotinamide adenine dinucleotide during ischemia-reperfusion in isolated hearts: reversal by 5-hydroxydecanoic acid. Anesthesiology 2003;98:387-95.
- 39. Schreiber SS, Reff F, Evans CD, Rothschild MA, Oratz M. Prolonged feeding of ethanol to the young growing guinea pig. III. Effect on the synthesis of the myocardial contractile proteins. Alcohol Clin Exp Res 1986;10:531-4.

Table Legend

Table 1: Data are presented as mean \pm SD. LVDP=left ventricular developed pressure; LVEDP=left ventricular end-diastolic pressure; CF=coronary flow; $+dP/dt_{max}=maximum$ rate of increase of LV pressure; $-dP/dt_{min}=maximum$ rate of increase of LV pressure; CTL=control; EtOH=ethanol; SEVO=sevoflurane CHE=chelerythrine; 5-HD=5-hydroxydecanoate. *p<0.05 vs. CTL, n=10 for each group

Figure Legends

Figure 1: Schematic illustration of the experimental protocol of this study. All hearts were subjected to 30 min global ischemia followed by 120 min reperfusion. Anesthetic preconditioning (APC) was elicited by administration of sevoflurane (2% or 1 MAC) for 10 min with a 10 min washout period. Ethanol-treated animals received 2.5% ethanol in their drinking water for 6 weeks. CTL=control; EtOH=ethanol; SEVO=sevoflurane; CHE=chelerythrine, PKC inhibitor; 5-HD=5-hydroxydecanoate, mitochondrial K_{ATP} channel inhibitor

Figure 2: Infarct size as a percentage of LV in eight groups. Treatment with sevoflurane (1 MAC) and 2.5 % ethanol for 6 weeks equally reduced infarct size compared with control. The combination of sevoflurane and 2.5 % ethanol conferred a further reduction of infarct size. This additional cardioprotective effect was abolished by CHE and 5-HD in SEVO+EtOH. 5-HD and CHE treatment alone did not affect infarct size. Data are presented as mean \pm SD. *p<0.001 vs. CTL, #p<0.001 vs. EtOH and SEVO

Figure 3: Western blot analysis of iNOS and eNOS from left ventricular samples before ischemia in control and ethanol-treated hearts (n=4 for each group). In ethanol-treated hearts, iNOS expression was significantly reduced and eNOS expression was significantly increased compared with control. *p<0.05 vs. CTL

	(CHE or 5HD) washout			reperfusion (min)		
	Dasenne	+SEVO/SEVO		i		
	-60	-40	-30	30	60	120
LVDP (mmHg)						
CTL	113±17			39±7	33±8	26±8
EtOH	104±14			60±13*	56±13*	47±11*
SEVO	101±13	100±12	103±12	61±9*	58±8*	50±8*
EtOH+SEVO	110±16	106±20	110±17	66±8*	61±8*	50±9*
CTL+CHE	109±13	108±15	97±17	26±12	27±12	26±12
EtOH+SEVO+CHE	100±8	99±12	88±18	30±10	29±10	29±9
CTL+5-HD	107±16	108±16	102±17	41±11	39±10	36±10
EtOH+SEVO+5-HD	111±7	112±14	106±14	38±13	35±10	32±8
LVEDP (mmHg)						
CTL	10±0			47±13	55±18	60±17
EtOH	10±0			24±21*	25±21*	27±20*
SEVO	10±0	10±3	10±2	24±7*	24±5*	26±7*
EtOH+SEVO	10±0	9±2	10±3	19±6*	20±6*	25±11*
CTL+CHE	10±0	10±3	13±7	52±20	49±23	48±24
EtOH+SEVO+CHE	10±0	10±2	15±13	46±17	50±19	49±20
CTL+5-HD	10±0	7±3	8±4	49±12	53±9	55±10
EtOH+SEVO+5-HD	10±0	8±4	10±4	56±18	58±17	57±19
CF (ml)						
CTL	28±7			27±9	28±10	28±11
EtOH	27±4			26±10	26±10	25±11
SEVO	31±7	29±4	27±4	25±7	25±7	24±7
EtOH+SEVO	26±6	30±7	25±5	21±4	20±3	20±3
CTL+CHE	28±8	31±8	26±9	21±7	21±7	20±8
EtOH+SEVO+CHE	28±7	32±8	26±9	20±9	20±9	19±9
CTL+5-HD	29±5	26±6	26±5	28±7	28±7	27±8
EtOH+SEVO+5-HD	27±4	24±4	22±3	22±7	21±7	21±7
+dP/dt _{max} (mmHg-Es ⁻¹))					
CTL	1735±310			786±185	674±218	544±168
EtOH	1433 ± 242			1114±197*	1085±212*	925±179*
SEVO	1479±251	1492±212	1529±224	1019±168*	1000±156*	910±124*
EtOH+SEVO	1588 ± 257	1604±285	1623±232	1156±159*	1133±132*	953±162*
CTL+CHE	1566±232	1676±297	1443±349	491±203	490±200	482±197
EtOH+SEVO+CHE	1442±145	1521 ± 205	1368 ± 268	572±176	576±161	537±175
CTL+5-HD	1635 ± 219	1683 ± 203	1656±174	730±212	700±200	660±225
EtOH+SEVO+5-HD	1653±137	1586±276	1485±259	625 ± 113	614±127	564±96
-dP/dt _{min} (mmHg-Es ⁻¹)						
CTL	-1470+252			-553+141	-483+124	-389+100
EtOH	-1197+274			-913+203*	-809+190*	-709+182*
SEVO	-1230+181	-1220+160	-1286+157	-815+120*	-771+109*	-694+106*
EtOH+SEVO	-1318+192	-1261+271	-1344+175	-889+118*	-853+114*	-699+171*
CTL+CHE	-1310+149	-1375+241	-1017+372	-355 ± 144	-367 ± 146	-375+153
EtOH+SEVO+CHE	-1321+155	-1254+152	-1081+280	-408 ± 142	-426 ± 139	-413+132
CTL+5-HD	-1473 ± 149	-1546 ± 209	-1510 ± 228	-523 ± 136	-486±113	-454 ± 108
EtOH+SEVO+5-HD	-1467 ± 151	-1548 ± 251	-1411 ± 265	-524 ± 146	-515±131	-378±356
CTL EtOH SEVO EtOH+SEVO CTL+CHE EtOH+SEVO+CHE CTL+5-HD EtOH+SEVO+5-HD CTL EtOH SEVO EtOH+SEVO CTL+CHE EtOH+SEVO+CHE CTL+5-HD EtOH+SEVO+5-HD + dP/dt_{max} ($mmHg-Es^{-1}$) CTL EtOH SEVO EtOH+SEVO CTL+CHE EtOH+SEVO+CHE CTL+5-HD EtOH+SEVO+CHE CTL+5-HD EtOH+SEVO+5-HD - dP/dt_{min} ($mmHg-Es^{-1}$) CTL EtOH SEVO EtOH+SEVO+CHE CTL+5-HD EtOH+SEVO+CHE CTL+5-HD EtOH+SEVO+CHE CTL+CHE EtOH+SEVO+CHE CTL+CHE EtOH+SEVO+CHE CTL+CHE EtOH+SEVO+CHE CTL+5-HD EtOH+SEVO+CHE CTL+5-HD	$\begin{array}{c} 10\pm 0\\ 28\pm 7\\ 27\pm 4\\ 31\pm 7\\ 26\pm 6\\ 28\pm 8\\ 28\pm 7\\ 29\pm 5\\ 27\pm 4\\ 1735\pm 310\\ 1433\pm 242\\ 1479\pm 251\\ 1588\pm 257\\ 1566\pm 232\\ 1442\pm 145\\ 1635\pm 219\\ 1653\pm 137\\ -1470\pm 252\\ -1197\pm 274\\ -1230\pm 181\\ -1318\pm 192\\ -1310\pm 149\\ -1321\pm 155\\ -1473\pm 149\\ -1467\pm 151\\ \end{array}$	$10\pm 3 \\ 9\pm 2 \\ 10\pm 3 \\ 10\pm 2 \\ 7\pm 3 \\ 8\pm 4 \\ 29\pm 4 \\ 30\pm 7 \\ 31\pm 8 \\ 32\pm 8 \\ 26\pm 6 \\ 24\pm 4 \\ 1492\pm 212 \\ 1604\pm 285 \\ 1676\pm 297 \\ 1521\pm 205 \\ 1683\pm 203 \\ 1586\pm 276 \\ -1220\pm 160 \\ -1261\pm 271 \\ -1375\pm 241 \\ -1254\pm 152 \\ -1546\pm 209 \\ -1548\pm 251 \\ \end{array}$	10 ± 2 10 ± 3 13 ± 7 15 ± 13 8 ± 4 10 ± 4 27 ± 4 25 ± 5 26 ± 9 26 ± 5 22 ± 3 1529 ± 224 1623 ± 232 1443 ± 349 1368 ± 268 1656 ± 174 1485 ± 259 -1286 ± 157 -1344 ± 175 -107 ± 372 -1081 ± 280 -1510 ± 228 -1411 ± 265	$\begin{array}{c} 47\pm13\\ 24\pm21*\\ 24\pm7*\\ 19\pm6*\\ 52\pm20\\ 46\pm17\\ 49\pm12\\ 56\pm18\\ \end{array}$ $\begin{array}{c} 27\pm9\\ 26\pm10\\ 25\pm7\\ 21\pm4\\ 21\pm7\\ 20\pm9\\ 28\pm7\\ 22\pm7\\ \end{array}$ $\begin{array}{c} 786\pm185\\ 1114\pm197*\\ 1019\pm168*\\ 1156\pm159*\\ 491\pm203\\ 572\pm176\\ 730\pm212\\ 625\pm113\\ \end{array}$ $\begin{array}{c} -553\pm141\\ -913\pm203*\\ -815\pm120*\\ -889\pm118*\\ -355\pm144\\ -408\pm142\\ -523\pm136\\ -524\pm146\\ \end{array}$	55 ± 18 $25\pm21*$ $24\pm5*$ $20\pm6*$ 49 ± 23 50 ± 19 53 ± 9 58 ± 17 28 ± 10 26 ± 10 25 ± 7 20 ± 3 21 ± 7 20 ± 9 28 ± 7 21 ± 7 674 ± 218 $100\pm156*$ $1133\pm132*$ 490 ± 200 576 ± 161 700 ± 200 614 ± 127 -483 ± 124 $-809\pm190*$ $-771\pm109*$ $-853\pm114*$ -367 ± 146 -426 ± 139 -486 ± 113 -515 ± 131	60 ± 17 $27\pm20*$ $26\pm7*$ $25\pm11*$ 48 ± 24 49 ± 20 55 ± 10 57 ± 19 28 ± 11 24 ± 7 20 ± 3 20 ± 8 19 ± 9 27 ± 8 21 ± 7 544 ± 168 $925\pm179*$ $910\pm124*$ $953\pm162*$ 482 ± 197 537 ± 175 660 ± 225 564 ± 96 -389 ± 100 -709 ± 182 -694 ± 106 -699 ± 171 -375 ± 153 -413 ± 132 -454 ± 108 -378 ± 356

Table 1. Hemodynamic Variables